(March 31 19:30) Forbes.com
We think that Alnylam Pharmaceuticals stock, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, currently is a better pick compared to Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, despite ALNY being the more...
You can find the original article
here